XNAS
LFVN
Market cap75mUSD
Oct 08, Last price
5.99USD
1D
-0.17%
1Q
-4.01%
Jan 2017
-26.50%
IPO
-74.61%
Name
LifeVantage Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LifeVantage Corporation (LFVN) specializes in the development, manufacture, and distribution of a diverse portfolio of health, wellness, and personal care products. Its offerings encompass nutrigenomic activators (designed to influence genetic expression), a broad array of dietary supplements, cognitive enhancers (nootropics), gut health support (pre- and pro-biotics), weight management solutions, and various personal care items spanning skin care, hair care, bath and body, and targeted relief. The company's product lineup features well-known brands such as Protandim, a series of scientifically validated dietary supplements. Specific examples include LifeVantage Omega+, a blend of DHA/EPA Omega-3s, Omega-7s, and Vitamin D3; LifeVantage ProBio, designed for digestive wellness; the PhysIQ brand for weight management; Petandim, tailored to reduce oxidative stress in dogs; and Axio energy drink mixes. Under the TrueScience brand, LifeVantage also provides anti-aging skincare (e.g., facial cleansers, perfecting lotions, eye serums, creams), hair care solutions (e.g., invigorating shampoos, nourishing conditioners, scalp serums), and an assortment of bath and body products (e.g., body lotion, wash, butter, deodorant) and targeted relief items (e.g., soothing balm, body rub). Distribution occurs through both its proprietary website and an extensive network of independent distributors. LifeVantage maintains a significant international presence, with operations spanning numerous global territories including the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. The corporation's headquarters are situated in Lehi, Utah.
Key people
Raymond Greer
Independent Chairman of the Board · since 2023
Carl Aure
Chief Financial Officer · since 2021
Michelle Oborn-Virchow
Chief People Officer · since 2022
Mike Edwards
Chief Technology Officer · since 2026
Kristen Cunningham
Chief Sales Officer · since 2022
Alissa Neufeld
General Counsel, Corporate Secretary · since 2021
Rajendran Anbalagan
Independent Director · since 2024
Independent Director · since 2024
Cynthia Latham
Independent Director · since 2022
Darwin Lewis
Independent Director · since 2017
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
9785 South Monroe Street
Suite 400
Sandy, UT 84070
US
Suite 400
Sandy, UT 84070
US
Previous name
Lifeline Therapeutics, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||